Charalampos Fotsitzoudis

Mr. Charalampos Fotsitzoudis

University General Hospital of Heraklion, Heraklion, Greece
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CFCharalampos Fotsitzoudis
Charalampos Fotsitzoudis
AKAsimina Koulouridi
Asimina Koulouridi
IMIppokratis Messaritakis
Ippokratis Messaritakis
Theocharis I KonstantinidisTheocharis I Konstantinidis
Theocharis I Konstantinidis
NGNIKOLAOS GOUVAS
NIKOLAOS GOUVAS
John SouglakosJohn Souglakos
John Souglakos
The therapeutic approaches to cancer remain a considerable target for all scientists around the world. Although new cancer treatments are an everyday phenomenon, cancer still remains one of the leading mortality causes. Colorectal cancer (CRC) remains in this category, although patients with CRC may have better survival compared with other malignancies. Not only the tumor but also its environment, what we call the tumor microenvironment (TME), seem to contribute to cancer progression and resistance to therapy. TME consists of different molecules and cells. Cancer-associated fibroblasts are a major component. They arise from normal fibroblasts and other normal cells through various pathways. Their role seems to contribute to cancer promotion, participating in tumorigenesis, proliferation, growth, invasion, metastasis and resistance to treatment. Different markers, such as a-SMA, FAP, PDGFR-β, periostin, have been used for the detection of cancer-associated fibroblasts (CAFs). Their detection is important for two main reasons; research has shown that their existence is correlated with prognosis, and they are already under evaluation as a possible target for treatment. However, extensive research is warranted.